Cargando…
Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine
In this phase 3 trial, Kampmann et al.(1) demonstrated safety and efficacy of a maternal bivalent RSV prefusion F vaccine. Vaccine efficacy was achieved in reducing severe RSV-associated lower respiratory tract infections in infants at 90 and 180 days following birth.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313928/ https://www.ncbi.nlm.nih.gov/pubmed/37343524 http://dx.doi.org/10.1016/j.xcrm.2023.101081 |